OMERS ADMINISTRATION Corp Has $35.93 Million Holdings in Johnson & Johnson $JNJ

Key Points

• OMERS ADMINISTRATION Corp increased its holdings in Johnson & Johnson, purchasing an additional 10,947 shares and boosting its total to 216,675 shares, valued at approximately $35.93 million.
• Analyst ratings for Johnson & Johnson show mixed sentiment, with two analysts giving a Strong Buy rating, while others have downgraded the stock, resulting in an average rating of "Moderate Buy" with a target price of $176.29.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, with an annualized dividend yield of 2.9%, reflecting a payout ratio of 55.61%.

OMERS ADMINISTRATION Corp boosted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 216,675 shares of the company's stock after buying an additional 10,947 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in Johnson & Johnson were worth $35,933,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of JNJ. Nuveen LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth $1,369,188,000. GAMMA Investing LLC boosted its holdings in Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock valued at $1,196,596,000 after purchasing an additional 7,185,977 shares during the period. Bank of New York Mellon Corp boosted its holdings in Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares during the period. Janus Henderson Group PLC boosted its holdings in Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock valued at $1,149,536,000 after purchasing an additional 4,559,147 shares during the period. Finally, Pacer Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 1,382.0% during the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock worth $502,509,000 after acquiring an additional 2,825,626 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Barclays raised their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. UBS Group raised their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Royal Bank Of Canada raised their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Finally, Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Stock Up 0.9%

JNJ traded up $1.65 during trading on Friday, reaching $177.10. 6,939,753 shares of the stock were exchanged, compared to its average volume of 8,399,834. The stock has a market cap of $426.52 billion, a P/E ratio of 18.94, a price-to-earnings-growth ratio of 2.23 and a beta of 0.41. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16. The stock's 50 day moving average price is $165.99 and its two-hundred day moving average price is $160.01. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the company earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.